

Steve Sisolak
Governor



Richard Whitley
Director

State of Nevada Department of Health and Human Services

Diabetic Supply

Educational Webinar

Division of Health Care Financing & Policy

Holly Long, SSPS III



March 24, 2020

Helping people. It's who we are and what we do.



Agenda

Policy & PA Overview

- Holly Long, MS, SSPS III, DHCFP

Omnipod®

- Michelle Tori, RD, CDCES, ADEPT Certified Medicaid Account Manager, Omnipod®

Dexcom G6®

- Carrie Sinnott, Regional Account Executive, Dexcom®

FreeStyle Libre 14 Day®

- Peter Johns, Regional Sales Director, Abbott Diabetes Care





Policy & PA Overview

- FFS only – does not apply to recipients enrolled in an MCO
- Preferred Diabetic Products: Omnipod, Dexcom G6 and FreeStyle Libre 14 Day
 - Includes tubeless insulin delivery system and CGM receivers and readers
 - Requires clinical PA for approval - Requires a diagnosis of DM1
- Preferred Diabetic Supplies
 - Includes sensors and transmitters
 - Does NOT require a PA - Requires a diagnosis of DM1





omnipod®
— DASH™

Michelle Tori, RD, CDCES, ADEPT Certified
Medicaid Account Manager - West

Insulet Corporation

Insulet Corporation

About Insulet



1,000+ employees



Direct operations

US, Canada and Europe



Innovation Focus

- Forbes 2017 - #4 on "Most Innovative Growth Companies"
- Innovation Technology Center in California



Manufacturing in the US

Plan to produce 3 million Pods from Acton, MA facility by the end of 2020

- Made in USA product for our USA customers
- Hired over 70 manufacturing jobs in USA



NEW Omnipod DASH™ System

The Power of Pod Therapy

Simple. Smart. Discreet

Tubeless,
Waterproof, Pod*

Remote Bolus Delivery for
Convenience

No Need to
Disconnect



Automatic Cannula
Insertion

Site Rotation Tracker

Convenient Pharmacy
Access

INSULIN MANAGEMENT SYSTEM

*The Pod has a waterproof IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof.

omnipod*

Intuitive and Simple to Use Color Touchscreen

- User-centric and modern design
- Secure, locked down smartphone
- Bluetooth® Wireless Technology
- Integrated CalorieKing®* food library
- Zero basal rate
- Fractional IC Ratios

Omnipod DASH™ System
PDM



INSULIN MANAGEMENT SYSTEM

*Available in the English language only


omnipod®

Easy to Use and Teach




1. Fill Pod with Insulin
2. Pair PDM and Pod
3. Apply Pod

Integrated CalorieKing®* Food Library




Ability to search for specific food items

Access to over 80,000 branded and unbranded foods



Can set frequently eaten foods as favorites

Can create series of customized meals



Simplifies carb counting


INSULIN MANAGEMENT SYSTEM

*Available in the English language only

omnipod®

Fine-Tuned Insulin Delivery

- Zero Basal
- Fractional I:C Ratios
- Site map tracks Pod changes & encourages site rotation




Access to Insulin Delivery via Mobile Apps-Now Available!

**Omnipod
DISPLAY™ App**



Secondary PDM display on personal smartphone*

**Omnipod
VIEW™ App**



12 caregivers can view Pod info on personal smartphone *

**Today View
Widget**



CGM and Pod single screen view on iOS devices**

INSULIN MANAGEMENT SYSTEM

*The following iOS 11.3 compatible smartphone devices are available for use with the Omnipod VIEW™ App: iPhone 5S, 6, 6 Plus, 6S, 6S Plus, SE, 7, 7 Plus, 8, 8 Plus, and iPhone X. Available with DASH™ PDM version 1.0.50 and above.

**The Dexcom System does not have integrated functionality with the Omnipod DASH™ System. iPhone widgets are mobile application shortcuts that are visible after swiping right from the home screen to the iPhone's Today View.*

omnipod®

Insulet Provided Glooko




- Allows upload in or outside of clinic
- Overlays data from Omnipod DASH™ System, CGMs, BG meters, and fitness devices
- Multiple reports: Summary, AGP, Calendar View, Logbook, Daily Summary, and Device Settings
- Enables population tracking



Tendency to use the same site



Need to find some privacy to discreetly administer an injection before every meal



Rely on memory and manual record for insulin information and food diary

Infusion Site

Meal Bolus Delivery

Insulin Management



Prompt patient to record infusion site



Deliver bolus discreetly from the PDM



Combined view of both PDM and CGM data**


INSULIN MANAGEMENT SYSTEM

*The following iOS 11.3 compatible smartphone devices are available for use with the Omnipod VIEW™ App: iPhone 5S, 5, 6 Plus, 6S, 6S Plus, SE, 7, 7 Plus, 8, 8 Plus, and iPhone X. Available with DASH™ PDM version 1.0.50 and above.

**The Dexcom System does not have integrated functionality with the Omnipod DASH™ System. iPhone widgets are mobile application shortcuts that are visible after swiping right from the home screen to the iPhone's Today View*.

omnipod®

BENEFIT: Improved Quality of Life



Self-reported outcomes represented graphically.

Survey of more than 1,200 Adults
with Type 1 Diabetes
Demonstrates Improved Quality of
Life

66% of Poddess™ would not be using a pump if not for the Omnipod® System*

INSULIN MANAGEMENT SYSTEM

*Spring 2018, Customer Satisfaction Survey, Orchard Hill Market Research - This survey was completed on a prior generation of the Omnipod® Insulin Management System. Data on file.
Polonsky WH et al. Diabetes Technol Ther. 2016;18(10):664-670..

omnipod®

Pod Therapy

The Easiest to Use Insulin Delivery System*

93%**

Of Podders™ said that
insulin delivery is easier
with the Omnipod®
System**

97%**

Of Podders™ would
recommend the
Omnipod® System to a
friend**



INSULIN MANAGEMENT SYSTEM

* Argent Study: The methodology analyzed the User Guides for several commercially available self-managed insulin delivery systems, including Insulin Omnipod® System, Tandem t:sim®, Medtronic MiniMed® 530G, MiniMed® 670G, and NovoLog® FlexPen® and formed a panel of Certified Diabetes Educators (CDEs) to evaluate which product, in their expert opinion, was the simplest to use.

** This survey was completed on a prior generation of the Omnipod® Insulin Management System. Data on file.

omnipod®

Risk Statement

Important Safety Information: The Omnipod DASH™ Insulin Management System is intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin. Additionally, the Omnipod DASH™ System is interoperable with a compatible blood glucose meter to receive and display blood glucose measurements. The Omnipod DASH™ System has been tested and found to be safe for use with the following U-100 insulin: Novolog®, Humalog®, Apidra®, Admelog® or Fiasp®. Refer to the Omnipod DASH™ Insulin Management System User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions.

© 2020 Insulet Corporation. Omnipod, the Omnipod logo, DASH, the DASH logo, Omnipod DISPLAY, Omnipod VIEW, Omnipod DEMO and Podder are trademarks or registered trademarks of Insulet Corporation. All rights reserved. Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care. The Bluetooth® word mark and logos are registered trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Insulet Corporation is under license. Glooko is a trademark of Glooko, Inc. and used with permission. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.



dexcomG6

Transforming Diabetes
Management By
Advancing CGM Technology



Smart devices sold separately.


dexcom[®]

LBL017962 Rev 001

dexcom[®]

CGM = continuous glucose monitoring.
Intended For Payer Audience Only

BGM or Intermittent Scan Monitoring Is Not Enough



- The **American Diabetes Association (ADA)** differentiates RT-CGM from IS-CGM.² All individuals with increased risk for hypoglycemia should consider RT-CGM over IS-CGM³
- The **Endocrine Society** excludes IS-CGM from its recommendations, noting that it does not offer “true CGM” in terms of providing alerts for high and low blood glucose levels⁴

BGM = blood glucose monitoring; CGM = continuous glucose monitoring; IS-CGM = intermittent scan continuous glucose monitoring; RT-CGM = real-time continuous glucose monitoring.

References: 1. Dexcom G6 CGM System User Guide, 2019. 2. American Diabetes Association. *Diabetes Care*. 2019; 42(Suppl 1): S71-S80. 3. Edelman SV, et al. *Diabetes Care*. 2018;41(11):2265-2274. 4. Peters AL, et al. *J Clin Endocrinol Metab*. 2016;101(11):3922-3937.

Intended For Payer Audience Only

The Unique Features of Dexcom G6 Improve Diabetes Management

The only provider of CGM systems **indicated for children aged 2 years and older**.^{1,2}

- Up to **288 continuous readings per day**¹

- **Exceptional accuracy**³
- Class II device designation³

- **Zero** fingersticks required^{1,*}

- Customizable alerts and a fixed Urgent Low alarm¹
- **Predictive Urgent Low Soon** alert¹

Data share features with up to **10 followers**^{1,†}

- Robust clinical evidence of **improved glycemic outcomes**^{4,5}



Smart devices sold separately.

Studies prove the clinical benefits of the differentiating attributes of Dexcom.^{6,7}

*If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

†Separate Follow app required.

CGM = continuous glucose monitoring.

References: 1. Dexcom G6 CGM System User Guide, 2019. 2. Dexcom. <https://www.dexcom.com/about-Dexcom>. 2019. Accessed June 19, 2019.


3. FDA. <https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-fully-interoperable-continuous-glucose-monitoring-system-streamlines-review>. 2018. Accessed June 19, 2019.

4. Beck RW, et al. JAMA. 2017;317(4):371-378. 5. Welsh JB, et al. Diabetes Technol Ther. 2019;21(3):128-132. 6. Pühr S, et al. J Diabetes Sci Technol. 2019; doi: 10.1177/1932296819840691. 7. Welsh JB, et al. Diabetes Ther. 2019;10(2):751-755.

Intended For Payer Audience Only

Dexcom G6 System

Approved March 27, 2018 for ages 2 years and older



G6 Sensor

- Factory calibrated
- Acetaminophen Blocking
- Improved accuracy
- 10 day sensor



G6 Auto Applicator

- Simple, one-handed application



G6 Transmitter

- 30% reduction in overall size



G6 Display Device

- Touch screen receiver
- Urgent low soon alert
- Android/iOs smart devices and wearables

Easy to Insert: Peel-Press-Push-Place



Clinical Study Results

- **100%** of all subjects rated the new applicator system as “very easy” or “somewhat easy”
- **84%** rated the system as “painless”
- **100%** of all subjects rated the instructions for sensor insertion to be “somewhat or very easy”

A Predictive Low Glucose Alert Can Help Patients Avoid Hypoglycemia, Independent of Screen View Frequency²

Dexcom's predictive alert **warns users of impending hypoglycemia**.¹



Enabling the Urgent Low Soon alert has been shown to significantly reduce hypoglycemia, regardless of user interaction with the device ^{2,a}	
Infrequent screen viewers (< 3.30 views per day)	Frequent screen viewers (> 8.25 views per day)
36% reduction in time spent in hypoglycemia < 70 mg/dL	Nearly 50% reduction in time spent in hypoglycemia < 70 mg/dL

93% of G6 users enabled the Urgent Low Soon alert.²

^aThe Puhr et al study examined 15,000 patients who used Dexcom G6 and its mobile app for at least 30 days with or without the Urgent Low Soon alert enabled. The Urgent Low Soon alert forecasts when glucose will be ≤ 55 mg/dL within 20 minutes. Patients who infrequently viewed the screen but had the alert enabled reduced their time spent in hypoglycemia by more than 36% compared to those with the Urgent Low Soon alert disabled. Frequent screen viewers reduced their time spent in hypoglycemia by nearly 50%.²

References: 1. Dexcom G6 CGM System User Guide 2019. 2. Puhr S, et al. *J Diabetes Sci Technol*. 2019; doi: 10.1177/1932296819840691.

Intended For Payer Audience Only

Dexcom Share and Follow Feature



Dexcom G6 allows for remote monitoring of the patient's glucose data, **increasing their circle of support.**



±Separate Dexcom Follow App required

dexcom

14

dexcom

Dexcom CLARITY Allows Patients to Share CGM Data With HCPs



Home user¹:


- View glucose patterns, trends, and statistics with the Dexcom CLARITY app
- Get weekly notifications to know how much time is spent in target range
- Regular push notifications facilitate coaching and decision support

Dexcom CLARITY is a cloud-based diabetes management software that helps patients and providers understand and analyze glucose patterns.¹



HCP²:

- Data can be shared with HCPs on an ongoing basis to make appointments more efficient
- Data available on demand
- No downloading required saves valuable time
- Graphs show patterns of hypoglycemia and hyperglycemia, allowing providers to prioritize problems and find diabetes management solutions



Being able to easily analyze glucose patterns helps patients and providers find diabetes management solutions.³

CGM = continuous glucose monitoring; HCP = healthcare provider.

References: 1. Dexcom G6 CGM System User Guide, 2019. 2. Dexcom. <https://www.dexcom.com/clarity>. Accessed June 19, 2019. 3. Lee V, et al. *Methods Inf Med.* 2017;56(7):e84-e91.

Intended For Payer Audience Only

How to Order Dexcom G6 at the Pharmacy



PRODUCT	QUANTITY	REFILLS	NDC
DEXCOM G6 RECEIVER KIT	1-PACK	ONCE A YEAR	08627-0091-11
DEXCOM G6 TRANSMITTER KIT	1-PACK	EVERY 3 MONTHS	08627-0016-01
DEXCOM G6 SENSOR KIT	3-PACK	EVERY 30 DAYS	08627-0053-03

Pharmacy Prior-Authorization



Nevada Medicaid

Submit fax request to: 855-455-3303

Please note: All information below is required to process this request.

Continuous Glucose Monitors (CGMs) Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Device Information (required)					
Device Name:			Additional Information:		
☐ Check if request is for continuation of therapy					
Clinical Information (required)					
Mark all that apply:					
☐ The recipient has a diagnosis of Diabetes Mellitus Type I or Gestational Diabetes. ICD-10 _____					
☐ The product requested is approved for the age of the recipient per the manufacture's label.					
☐ The recipient has been compliant on their current antidiabetic regimen for at least the last six months (requiring at least three injections per day).					
☐ The recipient has a documented history of recurring hypoglycemia.					
☐ The recipient has wide fluctuations in pre-meal blood glucose, history of severe glycemic excursion or experiencing "Dawn" phenomenon with fasting blood glucose exceeding 200mg/dL.					
☐ The recipient is currently using insulin pump therapy while continuing to need frequent dosage adjustments or experiencing recurring episodes of severe hypoglycemia (50 mg/dL).					
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?					

- Prescriber completes Optumx Rx Prior Authorization form
- Once authorized, please send prescription to pharmacy

<https://www.medicaid.nv.gov/providers/rx/rxforms.aspx>

Dexcom Support and Services



See what's in the box.

Find your illustrated **Dexcom G6 Start Here** guide and **Using Your Dexcom G6** guide.



Watch online tutorials.

dexcom.com/tutorials



Watch training videos.

dexcom.com/training-videos

We're here
to help.

Talk to the experts.

Technical Support

Available 24/7 for questions about product troubleshooting.
844-607-8398

Dexcom CARE®

Provides CGM training and guidance from a team of certified diabetes educators.
888-738-3646

Customer Sales Support

Assists with Dexcom orders.
888-738-3646



Provider and Pharmacy Resources

- Local Support:

Gretchen Anderson: NV Territory Business Manager
702-569-5855
gretchen.anderson@dexcom.com

- HCP and Pharmacy Education:

Visit our website: www.provider.dexcom.com

Safety Statement

BRIEF SAFETY STATEMENT

Indications for Use: The Dexcom G6 Continuous Glucose Monitoring System (Dexcom G6 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons age 2 years and older.

The Dexcom G6 System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions. Interpretation of the Dexcom G6 System results should be based on the glucose trends and several sequential readings over time. The Dexcom G6 System also aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments.

The Dexcom G6 System is also intended to autonomously communicate with digitally connected devices, including automated insulin dosing (AID) systems. The Dexcom G6 System can be used alone or in conjunction with these digitally connected medical devices for the purpose of managing diabetes.

Contraindication: Don't wear your CGM (sensor, transmitter, receiver, or smart device) for magnetic resonance imaging (MRI), computed tomography (CT) scan, or high-frequency electrical heat (diathermy) treatment. The G6 hasn't been tested in those situations. The magnetic fields and heat could damage the components of the G6, which may cause it to display inaccurate G6 sensor glucose readings (G6 readings) or may prevent alerts. Without G6 readings or alarm/alert notifications, you might miss a severe low or high glucose event.

Safety Statement

BRIEF SAFETY STATEMENT (CONT'D)

Warnings:

Read User Materials

Before you use your G6, carefully read the materials included with it. If you don't, you might:

- Not use the G6 correctly
- Not understand G6 information
- Affect how well it works

Don't Ignore Low/High Symptoms

Don't ignore how you feel. If your glucose alerts and readings don't match what you're feeling, use your blood glucose meter (meter) to make diabetes treatment decisions or, if needed, seek immediate medical attention. When in doubt, get your meter out.

No Number, No Arrow, No CGM Treatment Decision

If your G6 doesn't show a number or arrow, or your readings don't match your symptoms, use your meter to make diabetes treatment decisions. No number, no arrow, no treatment decision. When in doubt, get your meter out.

Don't Use If...

Do not use the G6 if you are pregnant, on dialysis, or critically ill. It is not known how different conditions or medications common to these populations may affect performance of the system. G6 readings may be inaccurate in these populations.

Follow G6 instructions. If you don't, you could have a severe low or high glucose event.

© 2019 Dexcom, Inc. All rights reserved. This product is covered by U.S. patent.

Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.

Thank you!



life. to the fullest.

Abbott

DIABETES CARE

The FreeStyle Libre 14 Day System Overview



Indications and Important Safety Information


FreeStyle Libre 14 day Flash Glucose Monitoring system is a continuous glucose monitoring (CGM) device indicated for replacing blood glucose testing and detecting trends and tracking patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments in persons (age 18 and older) with diabetes. The system is intended for single patient use and requires a prescription.

CONTRAINDICATIONS: Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.

WARNINGS/LIMITATIONS: Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The systems do not have alarms unless the sensor is scanned, and the systems contain small parts that may be dangerous if swallowed. The systems are not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes. When using FreeStyle LibreLink app, access to a blood glucose monitoring system is required as the app does not provide one. Review all product information before use or contact Abbott Toll Free (855-632-8658) or visit www.freestylelibre.us for detailed indications for use and safety information.

Features and Benefits

FreeStyle Libre 14 day System is a simple and accurate CGM for patients¹



2 out of 3 people with diabetes do not comply with blood glucose monitoring as prescribed²



FreeStyle Libre 14 day System provides a more complete glucose picture, helping patients make better treatment decisions*

1. FreeStyle Libre 14 day System User's Manual

2. Vincze, Gábor et al. The Diabetes Educator 30.1 (2004): 112-125.

* Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

FreeStyle Libre 14 day sensor is factory-calibrated CGM sensor to eliminate fingersticks for calibration

- **Small, discreet, and easy for patients¹**

- **Worn up to 14 days on back of upper arm**

Scan to activate and wait 1 hour for first glucose reading

- **Very thin filament¹**

Filament is <0.4mm thick and inserted 5mm beneath the skin to measure interstitial fluid

- **Water-resistant**

Exercise, shower, and swim² in a depth of up to 1 meter for 30 minutes

- **Automatically measures glucose readings day and night³**

Continuously measures glucose every minute and records readings every 15 minutes. Stores up to 8 hours of glucose data



Approximately quarter-sized

1. Data on file, Abbott Diabetes Care.

2. Sensor is water-resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes

3. Based on the sensor being replaced once every 14 days, and scanned at least once every 8 hours

FreeStyle Libre 14 day reader provides simple yet comprehensive data for better diabetes management¹

- **Real-time glucose readings with painless² scan**
Provides insightful glucose trend arrows and history
- **An easy scan shows the latest 8 hours of glucose history**
Captures data from sensor when it is within 1- 4 cm of the sensor



1. Mazze, Roger S Diabetes technology & therapeutics 7.5 (2005): 784-787.

2. Data on file, Abbott Diabetes Care.

FreeStyle LibreLink app provides easy access to glucose insights on compatible mobile devices*

Compatible

Free to download and compatible with and FreeStyle Libre 14 day sensors^{1,2}

User-friendly

Shows current glucose readings, trend arrow, trends and patterns on iPhone or Android*

Seamless

Automatically uploads glucose data to the patient's LibreView account³ and allows sharing of reports from the app




*The FreeStyle LibreLink app is compatible with NFC-enabled smartphones running Android OS 5.0 or higher and iPhone 7 or later running iOS 11 or later.


1. FreeStyle LibreLink app and the FreeStyle Libre 14 day readers have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose
2. FreeStyle Libre 14 day sensor communicates with the FreeStyle Libre 14 day reader or the FreeStyle LibreLink app that started it. However, if the sensor is started with the app first, the reader cannot be used during the remainder of the sensor wear period.
3. Patients require a LibreView, a service provided by Abbott and Newyu, inc, account to use FreeStyle LibreLink

FreeStyle Libre 14 day System allows patients to monitor and respond to changing glucose


Daily Patterns




Time In Target



Average Glucose



Low Glucose Events



FreeStyle Libre 14 day System is easy for people with diabetes to use¹

1 Easy to start



- Apply the sensor to back of the upper arm
- Sensor is worn for 14 days

2 Easy to scan



- Obtain real-time glucose readings with painless¹scan
- Each scan provides current glucose reading, 8 hour glucose history, and glucose trend arrow

3 Easy to review



- Review glucose readings and history on reader
- Glucose readings can be uploaded and viewed and shared on LibreView

LibreView is developed, distributed, and supported by NewYu, Inc. The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice. Trademarks are the property of their respective owners.

1. Data on file, Abbott Diabetes Care.

Accuracy

CGM reinvented for accuracy¹ without daily calibration

- **The first personal CGM able to maintain accuracy¹ over 14 days without the need for fingerstick calibration or sensor coding***
- **Factory calibration delivers clinically proven accuracy¹**
- **FreeStyle Libre 14 day system achieved a MARD of 9.4% over 14 days¹**




1. FreeStyle Libre 14 day System User's manual

* Calibration or coding not required by the user

Clinically proven to be accurate¹, stable and consistent over 14 days without the need for fingerstick calibration

Abbott's CGM technology reinvents accuracy¹ without need for daily calibration:

- Factory calibration eliminates patient calibration errors
- Wired enzyme technology ensures stable sensor performance²



1. FreeStyle Libre 14 day System User's Manual

2. Hoss, Udo, et al. Journal of diabetes science and technology 8.1 (2014): 89-94.

* MARD (mean absolute relative difference) is compared to reference YSI (Yellow Springs Instrument) values


FreeStyle Libre 14 day System delivers proven accuracy¹

High degree of agreement between sensor readings and YSI values²

89.5% of glucose results within Zone A

100% of glucose results within Zones A & B

- **Zone A:** No effect on clinical action (considered clinically accuracy)
- **Zone B:** Altered clinical action, but no or little effect on clinical outcome
- **Zone C:** Altered clinical action – likely to affect clinical outcome
- **Zone D:** Altered clinical action – could have significant medical risk
- **Zone E:** Altered clinical action – could have dangerous consequences




1. FreeStyle Libre 14 day System User's manual
2. Data on file. Abbott Diabetes Care


Clinical, Real-World Data, and Meta-analysis

In clinical trials, FreeStyle Libre 14 day System led to more frequent glucose monitoring

T1DM Patients (IMPACT trial)¹



T2DM Patients (REPLACE trial)²



1. Bolinder et al., The Lancet 388.10057 (2016): 2254-2263. Data from this study is collected from FreeStyle Libre System.
2. Haak et al., Diabetes Therapy 8.1 (2017): 55-73. Data from this study is collected from FreeStyle Libre System.

FreeStyle Libre 14 day System reduced time in hypoglycemia and hypoglycemia episodes

T1D Patients (IMPACT)¹

T2D Patients (REPLACE)²


Nocturnal hypoglycemia
<70 mg/dL



Serious hypoglycemia
<55 mg/dL



Hypoglycemia episodes



1. Bolinder et al., The Lancet 388.10057 (2016): 2254-2263. Data from this study is collected from FreeStyle Libre System.
2. Haak et al., Diabetes Therapy 8.1 (2017): 55-73. Data from this study is collected from FreeStyle Libre System.

FreeStyle Libre 14 day System demonstrated similar outcomes in real world data¹

> 680,000

readers¹

8.5B

glucose measurements¹

> 4

years of data¹

FreeStyle Libre 14 day
System users check
glucose frequently¹

12

average scans per day

1. Calliari, L. et al. Real-world flash glucose monitoring in Brazil: can sensors make a difference in diabetes management in developing countries? *Diabetol Metab Syndr* (2020)12:3. doi:10.1186/s13098-019-0513-z

In meta-analysis, FreeStyle Libre 14 day System showed greater HbA1c* reduction with higher initial HbA1c*¹

29 STUDIES

1723 PARTICIPANTS



A meta-analysis of clinical and real world observational studies among type 1 and type 2 people with diabetes was conducted to assess the impact of using the FreeStyle Libre 14 day System on HbA1c

HbA1c reduction was observed in the first 2 months and sustained over a 12-month period

1. Evans M, Welsh Z, Ellis S, Seibold A. The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies. Diabetes Ther 2019; Published online 14 Oct 2019; <https://doi.org/10.1007/s13300-019-00720-0>

* Average HbA1c



PATIENTS CAN DO IT WITHOUT FINGERSTICKS*



*Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.

FreeStyle, Libre, and related brand marks are trademarks of Abbott Diabetes Care Inc. in various jurisdictions. © 2020 Abbott. ADC-10090 v2.0 03/20







Preferred Product Information

- Omnipod Dash® 5, please contact (800) 591-3455, Option 2 and visit <https://www.myomnipod.com/DASH>
- Dexcom G6® products, please contact (702) 569-5855 and visit <https://provider.dexcom.com>
- FreeStyle Libre® Reader and Sensor, please contact (855) 632-8658 and visit <https://www.freestylelibre.us/system-overview/freestyle-14-day.html>





DHCFP Contacts & Resources

Holly M. Long, MS, SSPSS III, DHCFP, hlong@dhcfp.nv.gov

Pharmacy Inquiries: rxinfo@dhcfp.nv.gov

Diabetic Supply Program Web Site:

<https://www.medicaid.nv.gov/providers/rx/diabeticsupplies.aspx>

MSM Chapter 1200 Policy:

<http://dhcfp.nv.gov/Resources/AdminSupport/Manuals/MSM/C1200/Chapter1200/>

PA Forms: <https://www.medicaid.nv.gov/providers/rx/rxforms.aspx>

